362 related articles for article (PubMed ID: 12431963)
1. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ; Stinchcombe TE; Mitchell BS; Shea TC; Baldwin AS; Stahl S; Adams J; Esseltine DL; Elliott PJ; Pien CS; Guerciolini R; Anderson JK; Depcik-Smith ND; Bhagat R; Lehman MJ; Novick SC; O'Connor OA; Soignet SL
J Clin Oncol; 2002 Nov; 20(22):4420-7. PubMed ID: 12431963
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Holkova B; Perkins EB; Ramakrishnan V; Tombes MB; Shrader E; Talreja N; Wellons MD; Hogan KT; Roodman GD; Coppola D; Kang L; Dawson J; Stuart RK; Peer C; Figg WD; Kolla S; Doyle A; Wright J; Sullivan DM; Roberts JD; Grant S
Clin Cancer Res; 2011 May; 17(10):3388-97. PubMed ID: 21447728
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in hematologic malignancies.
Richardson PG; Hideshima T; Mitsiades C; Anderson K
Ann Med; 2004; 36(4):304-14. PubMed ID: 15224657
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
O'Connor OA
Curr Treat Options Oncol; 2004 Aug; 5(4):269-81. PubMed ID: 15233904
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
14. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2004 Jan; 145(2):67-74. PubMed ID: 14978877
[TBL] [Abstract][Full Text] [Related]
15. Clinical update: proteasome inhibitors in hematologic malignancies.
Richardson P
Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
[TBL] [Abstract][Full Text] [Related]
16. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
18. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
19. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Reece DE; Sanchorawala V; Hegenbart U; Merlini G; Palladini G; Fermand JP; Vescio RA; Liu X; Elsayed YA; Cakana A; Comenzo RL;
Blood; 2009 Aug; 114(8):1489-97. PubMed ID: 19498019
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
